Zandelisib with Continuous or Intermittent Dosing As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory B-cell Malignancy: a Multicentre, First-in-patient, Dose-Escalation and Dose-Expansion, Phase 1b Trial.
LANCET ONCOLOGY（2022）
Key words
B-Cell Receptor Signaling
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined